<DOC>
	<DOCNO>NCT02238145</DOCNO>
	<brief_summary>To obtain information tolerability efficacy Atrovent® inhaletten® treatment chronic obstructive airway disease condition daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study Atrovent® Inhaletten® Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Primarily patient gender , old 30 year , suffer chronic obstructive airway disease Only patient treat Atrovent® within last year consider inclusion Contraindications list Instructions Use/Summary Product Characteristics Atrovent® Inhaletten®</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>